THAKKAR ROOPAL 2004979 Data last updated 2024-05-15 07:34:05 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-22 | 2023-12-14 | 3 | Thakkar Roopal | SVP, GLOBAL THERAPEUTICS & CMO | holding | 30225.0 | 0 | 0.17 | 0.0 | Direct | Common Stock | ABBVIE INC. | NA | 1765.54 (ABBV) | ||
| 2024-02-20 | 2024-02-15 | 2024-02-15 | 4 | Thakkar Roopal | SVP, CMO, GLOBAL THERAPEUTICS | acq | 17796.0 | 63.17 | 0.1 | 0.0 | Direct | Common Stock | ABBVIE INC. | code A | 28173.0
|
1765.54 (ABBV) |
| 2024-03-01 | 2024-02-28 | 2024-02-28 | 4 | Thakkar Roopal | SVP, CMO, GLOBAL THERAPEUTICS | dsp | 4914.0 | 17.44 | 0.03 | 178.99 | Direct | Common Stock | ABBVIE INC. | code F | 23259.0 | 1766.47 (ABBV) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-22 | 2023-12-14 | 3 | Thakkar Roopal | SVP, GLOBAL THERAPEUTICS & CMO | holding | 40873.0
|
0 | 0.23 | 115.73 | Direct | Option (Right To Buy) | ABBVIE INC. | NA | 1765.54 (ABBV) | ||
| 2024-02-20 | 2024-02-15 | 2024-02-15 | 4 | Thakkar Roopal | SVP, CMO, GLOBAL THERAPEUTICS | acq | 13868.0 | 100.0 | 0.08 | 0.0 | Direct | Option (Right To Buy) | ABBVIE INC. | code A | 13868.0 | 1765.54 (ABBV) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)